Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity
Objective Targeting CD47 for cancer immunotherapy has been studied in many clinical trials for the treatment of patients with advanced tumors. However, this therapeutic approach is often hampered by on-target side effects, physical barriers, and immunosuppressive tumor microenvironment (TME).Methods...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-12-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/12/e009473.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841536265809297408 |
|---|---|
| author | Jie Chen Liu Yang Mengyuan Li Qian Ye Shibing Wang Zengpeng Li Wenbin Qian |
| author_facet | Jie Chen Liu Yang Mengyuan Li Qian Ye Shibing Wang Zengpeng Li Wenbin Qian |
| author_sort | Jie Chen |
| collection | DOAJ |
| description | Objective Targeting CD47 for cancer immunotherapy has been studied in many clinical trials for the treatment of patients with advanced tumors. However, this therapeutic approach is often hampered by on-target side effects, physical barriers, and immunosuppressive tumor microenvironment (TME).Methods To improve therapeutic efficacy while minimizing toxicities, we engineered an oncolytic vaccinia virus (OVV) encoding an anti-CD47 nanobody (OVV-αCD47nb). We demonstrated the specific binding activity of αCD47nb secreted from the virus-infected cells to CD47 and that both secreted αCD47nb and OVV-αCD47nb blocked the “don’t eat me” signal of macrophages.Results Intratumorally injected OVV-αCD47nb continuously releases the αCD47nb in tumor tissues, thereby conferring superior systemic activity against breast and colon tumor cells and prolonging survival compared with OVV control. Furthermore, treatment with OVV-αCD47nb also remodeled the TME, as shown by increased T cell infiltration, CD8+ T cell activation and tumor-associated macrophages polarization, significantly enhancing innate and adoptive immunity. Additionally, the inclusion of programmed cell death protein-1 inhibiting boosted the anticancer efficacy of OVV-αCD47nb and raised the full response rate in tumor-bearing animals.Conclusion Overall, our findings highlight the therapeutic potential of OVV-αCD47nb for breast and colon cancer, and demonstrate its ability to modulate the immune cell profiles within tumors. This has established a rationale for further exploring OVV-αCD47nb as a potential therapy in the clinic. |
| format | Article |
| id | doaj-art-8c0fcb4eefe445959052e37aff9799fa |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-8c0fcb4eefe445959052e37aff9799fa2025-01-14T20:40:11ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262024-12-01121210.1136/jitc-2024-009473Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunityJie Chen0Liu Yang1Mengyuan Li2Qian Ye3Shibing Wang4Zengpeng Li5Wenbin Qian6Department of Pharmacy, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, ChinaDepartment of Medical Oncology, Hangzhou Medical College, Hangzhou, Zhejiang, ChinaDepartment of Hematology, Zhejiang University, Hangzhou, Zhejiang, ChinaHangzhou Ronggu Biotechnology Limited Company, Hangzhou, ChinaDepartment of Clinical Laboratory, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, ChinaThird Institute of Oceanography Ministry of Natural Resources, Xiamen, ChinaDepartment of Hematology, Zhejiang University, Hangzhou, Zhejiang, ChinaObjective Targeting CD47 for cancer immunotherapy has been studied in many clinical trials for the treatment of patients with advanced tumors. However, this therapeutic approach is often hampered by on-target side effects, physical barriers, and immunosuppressive tumor microenvironment (TME).Methods To improve therapeutic efficacy while minimizing toxicities, we engineered an oncolytic vaccinia virus (OVV) encoding an anti-CD47 nanobody (OVV-αCD47nb). We demonstrated the specific binding activity of αCD47nb secreted from the virus-infected cells to CD47 and that both secreted αCD47nb and OVV-αCD47nb blocked the “don’t eat me” signal of macrophages.Results Intratumorally injected OVV-αCD47nb continuously releases the αCD47nb in tumor tissues, thereby conferring superior systemic activity against breast and colon tumor cells and prolonging survival compared with OVV control. Furthermore, treatment with OVV-αCD47nb also remodeled the TME, as shown by increased T cell infiltration, CD8+ T cell activation and tumor-associated macrophages polarization, significantly enhancing innate and adoptive immunity. Additionally, the inclusion of programmed cell death protein-1 inhibiting boosted the anticancer efficacy of OVV-αCD47nb and raised the full response rate in tumor-bearing animals.Conclusion Overall, our findings highlight the therapeutic potential of OVV-αCD47nb for breast and colon cancer, and demonstrate its ability to modulate the immune cell profiles within tumors. This has established a rationale for further exploring OVV-αCD47nb as a potential therapy in the clinic.https://jitc.bmj.com/content/12/12/e009473.full |
| spellingShingle | Jie Chen Liu Yang Mengyuan Li Qian Ye Shibing Wang Zengpeng Li Wenbin Qian Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity Journal for ImmunoTherapy of Cancer |
| title | Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity |
| title_full | Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity |
| title_fullStr | Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity |
| title_full_unstemmed | Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity |
| title_short | Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity |
| title_sort | oncolytic vaccinia virus armed with anti cd47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity |
| url | https://jitc.bmj.com/content/12/12/e009473.full |
| work_keys_str_mv | AT jiechen oncolyticvacciniavirusarmedwithanticd47nanobodyelicitpotentantitumoreffectsonmultipletumormodelsviaenhancinginnateandadoptiveimmunity AT liuyang oncolyticvacciniavirusarmedwithanticd47nanobodyelicitpotentantitumoreffectsonmultipletumormodelsviaenhancinginnateandadoptiveimmunity AT mengyuanli oncolyticvacciniavirusarmedwithanticd47nanobodyelicitpotentantitumoreffectsonmultipletumormodelsviaenhancinginnateandadoptiveimmunity AT qianye oncolyticvacciniavirusarmedwithanticd47nanobodyelicitpotentantitumoreffectsonmultipletumormodelsviaenhancinginnateandadoptiveimmunity AT shibingwang oncolyticvacciniavirusarmedwithanticd47nanobodyelicitpotentantitumoreffectsonmultipletumormodelsviaenhancinginnateandadoptiveimmunity AT zengpengli oncolyticvacciniavirusarmedwithanticd47nanobodyelicitpotentantitumoreffectsonmultipletumormodelsviaenhancinginnateandadoptiveimmunity AT wenbinqian oncolyticvacciniavirusarmedwithanticd47nanobodyelicitpotentantitumoreffectsonmultipletumormodelsviaenhancinginnateandadoptiveimmunity |